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Background: Angina without coronary artery disease (CAD) contributes to morbidity and is present in 10-30% of patients undergoing 
angiography. Fifty to 65% of these patients have coronary microvascular dysfunction (MVD). The optimal treatment of this cohort is 
undefined. We performed a systematic review to evaluate the effect of treatment for MVD in the absence of CAD.
methods: We performed a Medline search querying common terms used in describing angina without CAD. Articles were limited to English 
language reporting drugs or therapeutics in humans. Identified articles underwent single investigator review of title and abstract. Accepted 
articles were combined with articles from a bibliography search. These underwent review by two independent investigators based on 
inclusion (humans; coronary flow reserve (CFR) <2.5 by PET, CMR, dilution methods, or intracoronary Doppler; presence of angina) and 
exclusion (coronary artery stenosis ≥50%, structural heart disease) criteria.
results: A Medline search, accessed in the spring of 2014, identified 8,495 articles. Of these, 208 articles were identified for two-
investigator review. Only 8 articles met strict inclusion criteria. These articles studied sildenafil, quinapril, enalapril, L-arginine, diltiazem, 
doxazosin and TENS application. The articles were heterogenous using different primary end-points and different definitions. All but the 
L-arginine, diltiazem, and doxazosin trials demonstrated improvements in their respective end-points. Together these articles represent only 
6% of studies on the treatment of coronary MVD, averaging 11 patients per study,
Conclusion:  Our systematic review highlights that the data used to support therapies for MVD are inadequate. The heterogeneity 
in modes and protocols for defining coronary MVD make it challenging to compare treatment. Coronary MVD can now be identified 
noninvasively with high accuracy; however there is need for further refinement in techniques and definitions. We must take this opportunity 
to standardize protocols for the diagnosis of coronary MVD, allowing for future accurate population comparisons and advancements in 
therapy.
